Log in


Log in


If you have news that you would like distributed via HUPO's website, newsletter, or social media channels, please email office(at)

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 26 Jul 2021 1:11 PM | Anonymous member (Administrator)

    The Nominations and Elections Committee presents the official slate of candidates for the 2021 HUPO Council election. We would like to thank all candidates standing for Council election for a three-year term beginning in January 2022 (2022-2024). The election period for HUPO Council is October 26 – November 16, 2021.

    The list of candidates is available here. We encourage you to review the slate of candidates prior to the election opening date.

    HUPO members will receive a voting email from Simply Voting on October 26th

  • 26 Jul 2021 1:06 PM | Anonymous member (Administrator)

    Nominations are now open for HUPO Executive Committee positions. This is an opportunity to lead the future of an important scientific organization and work with an enthusiastic global team to promote and represent proteomics.

    The following positions will be elected by Council vote for a two-year term and commence in January 2022:

    • President-Elect (2022), President (2023-2024), Past President (2025)
    • Vice President (2022-2023)
    • ECR Representative (2022-2023) - appointed by the ECR, ratified by Council

    Click here to view a list of the current HUPO Executive Committee.

    For information on how to apply, please click here.

    The deadline to submit self-nominations is August 31, 2021.

    We look forward to your participation.

  • 28 Jun 2021 10:49 AM | Anonymous member (Administrator)

    Remembering a pioneering scientist, distinguished leader and our good friend on the journey to advance mass spectrometry-based proteomics

    We are deeply saddened by the loss of a distinguished colleague and friend in the HUPO community, Prof. Pengyuan Yang, Executive Vice Director of the BioMedical Sciences and Principal Researcher of the Biological Mass Spectrometry Group, Fudan University, in May 31, 2021.

    Pengyuan received his PhD from the department of chemistry, University of Massachusetts and worked as a post-doc in Indiana University and Xiamen University. He then joined Xiamen University and Fudan University to start his career. Throughout his life, Pengyuan has been devoted to the development of instrumentation and methodology in the fields of analytical chemistry and proteomics. Pengyuan pioneered mass spectrometry-based instrumentation and methodology when proteomics was still in its infancy. With his keen vision, he constructed the very first ESI-Q-TOF mass spectrometer in China and kept promoting the development of mass spectrometry instruments and their application in proteomics. Pengyuan has made extraordinary contributions to the development of proteomics research in China. He has led two national “973” projects aiming to develop advanced proteomics and microfluidics, starting in the historical period when scientists gradually shifted their 2D gel to mass spectrometry-based proteomics. He also led one national “863” project aiming to develop MS instrumentation and relevant reagents. He has published more than 500 articles with over 16,000 citations. In particular, he has developed a series of techniques for identification and quantification of the glycoproteome, in particular pGlyco. These “sweet” techniques and informatic tools will remain a great legacy to benefit the study of the highly complex glycobiology.

    We are so grateful to have Pengyuan with his life-long contribution to HUPO. Until the last stage in his life, Pengyuan actively participated in the Human Proteome Project (HPP) under HUPO. He served as an elected council member of HUPO, and past member-at-large of the Human Proteome Project (HPP), playing key role to direct and coordinate the activities of HPP.He also was a leading member under the Human Disease Glycomics/Proteome Initiative (HGPI). Aligned with the international efforts under the chromosome-centric Human Proteome Project (C-HPP), he also lead a team to decode the protein compositions of chromosome-8 and understand the biological context of the protein parts list. PangYuan’s passion, efforts and contribution to the proteomics community are highly recognized and appreciated.

    We believe that the spirit of PengYuan will live on. His legacy will be inherited by more researchers and continue to contribute to create new generations of instruments, applications of mass spectrometry and their translation into precision medicine. On behave of HUPO, we would like offer our condolences to Pengyuan's family.

    Yu-Ju Chen, President
    Susan E Weintraub, Vice President
    Henning Hermjakob, Secretary-general
    On behalf of Human Proteome Organization (HUPO)

    Huali Shen, Professor
    On behalf of Pengyuan Yang’s group

  • 23 Jun 2021 11:31 AM | Anonymous member (Administrator)

    The HUPO Proteomics Knowledge Resource is now available - a virtual library where you can view posters, recordings, training courses and industry seminars from HUPO Connect 2020. Generally, selected presentations become available six months after the original presentation. The content will be available year-round and can be accessed on-demand, for free, by all HUPO members. 

    HUPO Connect 2020 recordings are now available:

    • 40 recordings from the main program
    • 6 pre-congress webinars
    • 45 pre-congress training courses
    • 220 posters
    • 16 industry seminars

    The content will be available year-round and can be accessed on-demand, for free, by all HUPO members. We will continuously be adding new content.

  • 28 May 2021 4:35 PM | Anonymous member (Administrator)

    Written by Emily Hashimoto-Roth, University of Ottawa, Canada

    The HUPO Early Career Researcher Initiative is excited to announce the return of its Poster Competition for HUPO Reconnect 2021. Starting this year, the competition now opens to both Master’s and Ph.D. students to maximize inclusivity. Selected posters will have the opportunity to give a short talk at HUPO Reconnect 2021 and the best presentations will be awarded cash prizes. More details will be provided shortly regarding registration to the competition.

  • 28 May 2021 4:33 PM | Anonymous member (Administrator)

    Written by Emily Hashimoto-Roth, University of Ottawa, Canada

    In partnership with the European Proteomics Association’s Young Proteomics Investigators Club (YPIC), the HUPO Early Career Researcher Initiative hosted its first online panel discussion on May 17th at 7PM EDT (GMT-4/New York Time). Our panelists, Dr. Yu-Ju Chen (Academia Sinica, Taiwan), Dr. Renã A. S. Robinson (Vanderbilt University, USA), and Dr. Robert Rivers (National Institutes of Health, USA), shared their insights on the importance of promotion of diversity in proteomics, which sparked lively conversations with attendees in the audience. Thank you to everyone who attended, our panelists, and our panel chair, Emily Hashimoto-Roth (University of Ottawa)!

    Our next panel will cover managing expectations between a supervisor and oneself and be taking place in July. Stay tuned for more details and registration information!

  • 28 May 2021 4:31 PM | Anonymous member (Administrator)

    Written by Emily Hashimoto-Roth, University of Ottawa, Canada

    Are you an early career researcher who published, or had a paper accepted for publication, after January 1st, 2020? We highly encourage you to submit your manuscript to the ECR Manuscript Competition! Eligible early career researchers include post-doctoral fellows (Ph.D. awarded post January 2015), faculty members (appointed post January 2017, with Ph.D. awarded post January 2009), and clinicians (M.D. awarded post January 2014), all of whom must also be HUPO members. Following deliberation by a selection committee, three finalists will have the opportunity to give an oral presentation at HUPO Reconnect 2021, where awards and cash prizes will be granted – $1,000 to the winner and $500 to the two runners-up. For complete competition details and to learn how to submit your manuscript, please visit: The deadline to submit is June 14th, 2021.

  • 28 May 2021 3:54 PM | Anonymous member (Administrator)

    Written by Daniella H. Hock, Department of Biochemistry and Pharmacology, Bio21 Institute, The University of Melbourne, Australia; David Thorburn, Murdoch Children’s Research Institute, Royal Children’s Hospital, Department of Paediatrics, University of Melbourne, Victorian Clinical Genetics Services, Murdoch Children’s Research Institute, Royal Children’s Hospital, Australia; David A. Stroud,  Department of Biochemistry and Pharmacology, Bio21 Institute, The University of Melbourne, Australia

    Mitochondria are central to energy metabolism, producing the vast majority of cellular ATP via the oxidative phosphorylation (OXPHOS) system, while also being involved in other important processes such as one carbon metabolism, calcium homeostasis, and Fe-S cluster biogenesis (1, 2). Mitochondria are fascinating organelles as they possess their own circular DNA (mtDNA) which encodes 13 proteins translated via their own ribosomes (mitoribosome) while the remaining proteins are translated in the cytosol and imported into the mitochondria (3).

    Mitochondrial disease is an umbrella term for a collection of rare genetic disorders where cells fail to produce enough energy for proper organ and tissue function (2, 4). Collectively, it affects at least 1 in 5,000 live births (5) with infants affected by the disease having a particularly poor prognosis. From the over 1,100 known proteins localised to the human mitochondria (6), at least 350 are encoded by genes in which mutations are known to cause mitochondrial disease (4). Mitochondrial disease displays extreme clinical and genetic heterogeneity, can develop at any stage of life, and usually affects organs with high energy demand such as brain, heart, liver and skeletal muscle (2, 4).

    Once mitochondrial disease is suspected based on clinical investigation, the search for the genetic variant starts (Fig. 1A). The current diagnostic paradigm typically involves massively parallel sequencing (MPS) approaches such as whole-exome sequencing (WES) and whole-genome sequencing (WGS). Despite these combined approaches, the diagnosis of mitochondrial disease is only achieved in 35-60% of suspected cases and often after years of investigation (7). For some unsolved cases, more than one variant of uncertain significance (VUS) is flagged following bioinformatic analysis, potentially requiring further functional validation to confirm pathogenicity e.g., spectrophotometric assays of OXPHOS enzyme activity and western blot analysis of single proteins. Alternatively a single pathogenic variant is found in a gene associated with autosomal recessive inheritance and it can be unclear if a second “cryptic variant” has been missed. More recently high throughput omic approaches, such as transcriptomics and proteomics, have begun to be integrated into investigations of variant pathogenicity (8). The ‘unbiased’ nature of these techniques also lends themselves to gene discovery in cases where no candidate VUS are identified. The integration of multi-omic approaches into the diagnosis of mitochondrial disease is thus not only decreasing the waiting time for a diagnosis but potentially allowing an earlier use of therapies, disease management and facilitating provision of information that can inform family planning decisions.

    Since 2017 we have been developing and applying quantitative proteomics approaches to undiagnosed cases of rare diseases with a focus on patients with clinically suspected mitochondrial disease, while also investigating genes that can potentially cause mitochondrial diseases (9). We have analysed a range of primary tissues, including fibroblasts from skin biopsies, lymphoblasts from blood, myoblasts, skeletal muscle and heart biopsies, and have tested different quantitative approaches to individually address each clinical case. At its most basic, we have applied label free quantitative analysis of proteome changes in whole patient material relative to a panel (usually 3-5) of controls (Fig. 1B). We have also employed fractionation of peptides for increased proteome depth, pulse labelling with stable isotopes to monitor mtDNA translation, isobaric labelling, and other approaches. Our efforts have supported the published (10-13) and unpublished diagnosis of over 30 patients, many of whom were undiagnosed for decades after extensive investigation, thus demonstrating that quantitative proteomics is a technique capable of providing evidence to support disease causation arising from various types of variants, including deep intronic variants, splice site variants, copy number variants, and missense variants present in either mitochondrial or nuclear DNA.

    The first cold case we would like to share had been undiagnosed for over 10 years, despite inconclusive results after extensive investigations which included [i] chromosomal microarray and breakage analysis, [ii] quad (both parents and affected siblings) whole exome sequencing, [iii] common mitochondrial DNA point mutations, [iv] and the gold-standard quad whole genome sequencing (11). Transcriptomic analysis (RNA sequencing) was performed and identified a reduction in NDUFB10 expression as well as novel splicing events, including the presence of a cryptic exon in NDUFB10 transcripts (Fig. 1C). We performed label free quantitative proteomics on skin fibroblasts from the patient and three control individuals. NDUFB10 peptides were actually not detected in control or patient cells but we confirmed the reduction in over twenty NDUFB10 partner proteins in patient cells, similar to the protein signature observed in knockout NDUFB10 cells (14). These proteins, along with NDUFB10 are subunits of the first complex in the mitochondrial respiratory chain, also called Complex I or NADH ubiquinone oxidoreductase. The abundance of subunits in the other complexes of the OXPHOS system were unaffected. Reanalysis of WGS data confirmed the presence of a novel deep intronic cryptic splicing variant in NDUFB10, found in homozygosity in the affected siblings and in heterozygosity in the parents.

    The second investigation involves the diagnosis of 17 patients where inherited deletions and de novo duplication had occurred in the repetitive ATAD3 locus. Mutations in this locus are now known to be one of the five most common causes of paediatric nuclear-encoded mitochondrial disease (12). The ATAD3 locus is comprised of three highly homologous genes in tandem: ATAD3C, ATAD3B and ATAD3A, an arrangement which is exclusive to hominids. The homology of the region makes it prone to nonallelic homologous recombination (NAHR) events, giving rise to copy number variations (CNVs) such as deletions and duplications. Identification of deletions and duplications events in highly homologous genomic regions can be a challenge as these regions can be refractory to the short read sequencing approaches used in WES and WGS methodologies. To overcome this problem, short read approaches were combined with long-read sequencing, transcriptomics and quantitative proteomics analyses to identify recessive biallelic deletions and dominant de novo duplications in the ATAD3 locus (Fig.1D). At the protein level, the recessive biallelic deletions give rise to a fused ATAD3B/ATAD3A protein, while the dominant de novo duplication give rise to a chimeric ATAD3A/ATAD3C protein.

    Quantitative proteomics was shown to provide valuable functional data that can add to the body of evidence needed to confirm pathogenicity of VUS in rare and long-term undiagnosed cases. Our current efforts are now focused on developing a high throughput and robust quantitative proteomics pipeline to be incorporated into routine clinical investigations of patients with suspected but undiagnosed rare disease in order to decrease the current diagnostic gap.

    Figure 1A. Example pipeline for investigation of clinically suspected rare disease. Genomic sequencing is the first line approach followed by functional validation of variants of uncertain significance (VUS) using e.g. enzymology, western blot, transcriptomics and proteomics. B. General schematic depicting workflow for functional validation of VUS via quantitative proteomics. C. Multi-omic investigation used to identify a deep intronic variant in NDUFB10, a structural subunit of mitochondrial Complex I (CI). Transcriptomic analysis identified a cryptic exon inserted between exon 1 and exon 2 of NDUFB10. Proteomics on the patient skin fibroblasts show an isolated decrease in CI. Differential protein abundances were topographically mapped to the CI structure (PDB ID: 5LDW) for visualization of the impact of mutation. Data plotted from supplemental material in (11). D. Pathogenic genetic arrangements in the ATAD3 locus identified in patients with a large deletion or duplication in the repetitive ATAD3 locus. Deep peptide fractionation and label free quantitative proteomics of patient skin fibroblasts revealed the corresponding decrease and increase in peptide abundance. Data plotted from supplemental material in (12).


    1. Jackson TD, Hock DH, Fujihara KM, Palmer CS, Frazier AE, Low YC, et al. The TIM22 complex mediates the import of sideroflexins and is required for efficient mitochondrial one-carbon metabolism. Mol Biol Cell. 2021;32(6):475-91.

    2. Frazier AE, Thorburn DR, Compton AG. Mitochondrial energy generation disorders: genes, mechanisms, and clues to pathology. J Biol Chem. 2019;294(14):5386-95.

    3. Kang Y, Fielden LF, Stojanovski D. Mitochondrial protein transport in health and disease. Semin Cell Dev Biol. 2018;76:142-53.

    4. Hock DH, Robinson DRL, Stroud DA. Blackout in the powerhouse: clinical phenotypes associated with defects in the assembly of OXPHOS complexes and the mitoribosome. Biochem J. 2020;477(21):4085-132.

    5. Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain. 2003;126(Pt 8):1905-12.

    6. Rath S, Sharma R, Gupta R, Ast T, Chan C, Durham TJ, et al. MitoCarta3.0: an updated mitochondrial proteome now with sub-organelle localization and pathway annotations. Nucleic Acids Res. 2021;49(D1):D1541-D7.

    7. Stenton SL, Prokisch H. Genetics of mitochondrial diseases: Identifying mutations to help diagnosis. EBioMedicine. 2020;56:102784.

    8. Alston CL, Stenton SL, Hudson G, Prokisch H, Taylor RW. The genetics of mitochondrial disease: dissecting mitochondrial pathology using multi-omic pipelines. J Pathol. 2021.

    9. Hock DH, Reljic B, Ang CS, Muellner-Wong L, Mountford HS, Compton AG, et al. HIGD2A is required for assembly of the COX3 module of human mitochondrial complex IV. Mol Cell Proteomics. 2020.

    10. Lake NJ, Webb BD, Stroud DA, Richman TR, Ruzzenente B, Compton AG, et al. Biallelic Mutations in MRPS34 Lead to Instability of the Small Mitoribosomal Subunit and Leigh Syndrome. Am J Hum Genet. 2017;101(2):239-54.

    11. Helman G, Compton AG, Hock DH, Walkiewicz M, Brett GR, Pais L, et al. Multiomic analysis elucidates Complex I deficiency caused by a deep intronic variant in NDUFB10. Hum Mutat. 2021;42(1):19-24.

    12. Frazier AE, Compton AG, Kishita Y, Hock DH, Welch AE, Amarasekera SSC, et al. Fatal perinatal mitochondrial cardiac failure caused by recurrent de novo duplications in the ATAD3 locus. Med (N Y). 2021;2(1):49-73.

    13. Van Bergen NJ, Ahmed SM, Collins F, Cowley M, Vetro A, Dale RC, et al. Mutations in the exocyst component EXOC2 cause severe defects in human brain development. J Exp Med. 2020;217(10).

    14. Stroud DA, Surgenor EE, Formosa LE, Reljic B, Frazier AE, Dibley MG, et al. Accessory subunits are integral for assembly and function of human mitochondrial complex I. Nature. 2016;538(7623):123-6.


    Daniella Hock is a PhD candidate in Dr David Stroud’s lab at the University of Melbourne in Australia, where she has been developing and applying quantitative proteomics approaches to improve the diagnostic rates of rare diseases, particularly paediatric mitochondrial disease. She is also interested in investigating the molecular function of genes implicated in mitochondrial disease pathogenesis with a view toward expanding the list of genes that can potentially cause mitochondrial disease. Prior to commencing her PhD, Daniella graduated as Bachelor of Biological Sciences from Universidade Federal de Santa Catarina in Brazil and worked as molecular diagnostic scientist at Biogenetika, a personalised medicine centre, in Brazil.

  • 28 May 2021 3:48 PM | Anonymous member (Administrator)

    Written by Aleksandra Nita-Lazar, National Insitute of Allergy and Infectious Diseases, USA

    The diversity concept is being widely applied and more and more often globally recognized – and HUPO is no exception. For a long time, HUPO has been committed to the principles of diversity, and this commitment is reflected in our membership and leadership. Welcoming differences, equal opportunity, diversity, and inclusion is not only a matter of civility, but a real benefit for any creative effort. Diversity has been long known as a biological force driving functional ecosystems, and genetic diversity in any population ensures biological success. More recently, diversity has been recognized and published in numerous reports and books reviewing the relevant research (to name a few excellent examples: ”Creativity and Problem Solving” by Scott Page; “Accuracy in Decision-making” by Katherine Phillips” and “Willful Blindness” and other books by Margaret Heffernan), demonstrating that any diverse group will always do better than a uniform one, bringing unique perspectives and abilities, fostering discovery, boosting innovation and preventing decision bias. Each individual brings unique capabilities, experiences, and characteristics, their own vision, igniting creativity and fueling resourcefulness. To gain access to the best ideas we need to create an environment where people feel supported, heard, and free to achieve their best and contribute to their full potential. The synergy of diverse teams is real.

    At HUPO we are connected by a common interest in all aspects of proteome research; bringing our individual experiences will strengthen the organization further, so we intentionally cultivate diversity and inclusion. The members of HUPO represent scientists from all regions and levels – we have 48% student and Postdoc members and 38% of HUPO members are women. All the active members are eligible for election to the HUPO Council. The Nominations and Elections Committee (NEC) monitors and approves the nomination and election process. Two years ago, the requirement of 10 or more years of professional experience for eligibility was waived and now trainees and junior scientists are eligible and encouraged to be nominated. To promote diversity and reduce the dominance of well-known senior scientists in HUPO elections, each of the three regions (Eastern, Central and Western) has the authority to nominate two diversity candidates for each election, and these candidates are not directly voted on, but approved or not by the voting members. At present, 31% of the Council are the diversity delegates.

    The NEC is currently looking for a new co-chair committed to improving the diversity within the HUPO leadership. HUPO members interested in this position and in making their vision and ideas a reality are encouraged to apply! Contact

  • 20 Apr 2021 12:24 PM | Anonymous member (Administrator)

    Connect with leaders of the Biology/Disease-Driven Human Proteome Project (B/D-HPP) at their first PTMs in Human Disease webinar focused on showcasing approaches to investigate post-translational modifications (PTMs). This webinar will consist of seven (7) presentations and a panel discussion among speakers and participants.

    See list of speakers and presentation topics here: Webinar Flyer

    Date: Monday, April 26, 2021

    Time: 0600 PST; 0900 EST; 1300 UTC (Three (3) hours) Find your local time zone

    Zoom meeting link:

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

The Human Proteome Organization is a 501(c)(3) tax exempt non-profit organization registered in the state of New Mexico.  |  © 2021 HUPO

Powered by Wild Apricot Membership Software